Clinical Trial Update: Sorafenib Tosylate and Chemoembolization in Treating Patients With Unresectable Liver Cancer [Phase 1]

View source ↗

Summary

Phase 1 study assessing the safety of combining sorafenib tosylate with chemoembolization in patients with unresectable hepatocellular carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma
• Unresectable Hepatocellular Carcinoma

Drugs mentioned

• Nexavar (sorafenib tosylate) (sorafenib tosylate)

Snippet

Sponsor: Abramson Cancer Center at Penn Medicine | Conditions: Hepatocellular Carcinoma, Liver Cancer | Phase 1 | Status: COMPLETED